Health-care shares were higher as focus shifts to the beginning of earnings season. Celgene shares rose after the company reported positive results from a late-stage trial of a treatment for breast cancer, saying the trial met its co-primary endpoint of progression-free survival. In addition, on Monday evening Celgene and Acceleron Pharma reported positive results from a phase 3 trial of their drug Luspatercept, a drug to treat chronic anemia, beta-thalassemia and myelofibrosis.

Write to Amy Pessetto at amy.pessetto@dowjones.com

(END) Dow Jones Newswires

July 10, 2018 17:13 ET (21:13 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Celgene Charts.